Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03761017 | MGD019 DART® Protein in Unresectable/Metastatic Cancer | completed | Phase 1 | 162 | MacroGenicsINDUSTRY | 5 | Mar 6, 2025 | clinicaltrials |
| NCT05260684 | Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US(OCEANMIST) | completed | — | 716 | PfizerINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT05697198 |
| PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine(PREFER) |
| completed |
| — |
| 1,429 |
| Labcorp Corporation of America Holdings, IncINDUSTRY |
| 1 |
| Mar 6, 2025 |
| clinicaltrials |
| NCT06495008 | Taste and Smell Dysfunction in Patients More Than Two Years After Start of Immune Checkpoint Inhibitor Therapy(TasteSPICIER) | completed | — | 101 | University Medical Center GroningenOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT04417530 | Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma | completed | Phase 2 | 22 | Aura BiosciencesINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT05297565 | A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection(CheckMate-6GE) | completed | Phase 3 | 14 | Bristol-Myers SquibbINDUSTRY | 7 | Feb 27, 2025 | clinicaltrials |
| NCT06168825 | Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive Intervention(MOM) | completed | — | 40 | Inova Health Care ServicesOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT01338389 | Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy | completed | N/A | 21 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT03047928 | Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 48 | Inge Marie SvaneOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT01986712 | A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma | completed | — | 50 | St. Luke's Hospital and Health Network, PennsylvaniaOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03784625 | Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012(MELRIV-1) | completed | Early Phase 1 | 10 | Centre Jean PerrinOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03475134 | TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL) | completed | Phase 1 | 18 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT03665597 | Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) | completed | Phase 1 | 138 | Merck Sharp & Dohme LLCINDUSTRY | 4 | Feb 10, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT05172232 | Diagnostic Precision of the AI Tool Dermalyzer to Identify Malignant Melanomas in Subjects Seeking Primary Care for Melanoma-suspected Cutaneous Lesions(AI-DSMM) | completed | — | 231 | Linkoeping UniversityOTHER_GOV | 1 | Feb 5, 2025 | clinicaltrials |
| NCT05954546 | A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings | completed | — | 275 | PfizerINDUSTRY | 1 | Feb 5, 2025 | clinicaltrials |
| NCT02993315 | Melanoma Patients Immunized with Natural DenDritic Cells(MIND-DC) | completed | Phase 3 | 148 | Radboud University Medical CenterOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT02819843 | A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors | completed | Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06469138 | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects(8479217) | completed | Phase 1 | 6 | BerGenBio ASAINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT02936388 | Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis(SirTac) | completed | Phase 2 | 108 | Charite University, Berlin, GermanyOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT03154190 | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer | completed | N/A | 128 | Stanford UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT04146324 | An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia | completed | — | 150 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 24, 2025 | clinicaltrials |
| NCT03026517 | Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma | completed | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT02500576 | Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT03504488 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) | completed | Phase 1 / Phase 2 | 132 | BioAtla, Inc.INDUSTRY | 6 | Jan 15, 2025 | clinicaltrials |
| NCT01902173 | Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer | completed | Phase 1 / Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2025 | clinicaltrials |
| NCT02872259 | BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma | completed | Phase 1 / Phase 2 | 74 | Haukeland University HospitalOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT04382664 | UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma | completed | Phase 2 | 156 | Ultimovacs ASAINDUSTRY | 4 | Jan 14, 2025 | clinicaltrials |
| NCT04969419 | Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo | completed | — | 75,771 | Momentum DataINDUSTRY | 1 | Jan 14, 2025 | clinicaltrials |
| NCT01884961 | Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2(IL2HD) | completed | Phase 2 | 46 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT03033576 | Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma | completed | Phase 2 | 94 | National Cancer Institute (NCI)NIH | 1 | Jan 13, 2025 | clinicaltrials |
| NCT01973322 | Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study(ABSIDE) | completed | Phase 2 | 34 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05031494 | A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers | completed | Phase 2 | 40 | Eucure (Beijing) Biopharma Co., LtdINDUSTRY | 2 | Jan 6, 2025 | clinicaltrials |
| NCT05420324 | A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma | completed | Phase 2 | 20 | Eucure (Beijing) Biopharma Co., LtdINDUSTRY | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT03092453 | Dendritic Cell Vaccination in Patients With Advanced Melanoma | completed | Phase 1 | 5 | University of PennsylvaniaOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT02275416 | Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma | completed | Phase 1 / Phase 2 | 12 | Ultimovacs ASAINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT03153085 | A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma | completed | Phase 2 | 28 | Takara Bio Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03130569 | Skin Health Online for Melanoma: Better Risk Assessment(SOMBRA) | completed | N/A | 600 | University of New MexicoOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT02301611 | Phase IIB TL + YCWP + DC in Melanoma | completed | Phase 2 | 187 | Elios Therapeutics, LLCINDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT00975520 | Neurotropic Melanoma of the Head and Neck(RTN2) | completed | N/A | 50 | Melanoma and Skin Cancer Trials LimitedOTHER | 3 | Nov 27, 2024 | clinicaltrials |
| NCT02392871 | Radiotherapy & Combi in Metastatic Melanoma(CombiRT) | completed | Phase 1 / Phase 2 | 10 | Melanoma and Skin Cancer Trials LimitedOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT02791594 | Imaging FDG Flare in Melanoma | completed | — | 21 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT04504669 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | completed | Phase 1 | 60 | AstraZenecaINDUSTRY | 4 | Nov 5, 2024 | clinicaltrials |
| NCT05169957 | Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) | completed | Phase 1 | 2 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04096638 | Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 61 | invoX Pharma LimitedINDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 6, 2025source: clinicaltrials